Cited by 117Heart Rate Variability and Autonomic ControlCardiac Health and Mental HealthHeart rate and cardiovascular health

Effects of drug, biobehavioral and exercise therapies on heart rate variability in coronary artery disease: a systematic review

Nolan, Robert P., Jong, Philip, Barry-Bianchi, Susan M., Tanaka, Tim H., Floras, John S.·2008·European Journal of Cardiovascular Prevention & Rehabilitation

Abstract

BACKGROUND: Heart rate variability (HRV) is reported as a surrogate index for clinical outcome in trials of secondary prevention strategies for coronary artery disease (CAD), but a standardized guide for interpreting HRV change is not established. DESIGN: We evaluated HRV change in trials with CAD patients who received conventional medications (beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors), biobehavioral treatment (psychotropics, biofeedback, relaxation) or exercise training. METHODS: Medline, Pubmed, Psycinfo, the Cochrane database, and Embase were searched until July 2007, without language restriction. We identified 33 randomized controlled trials. Two reviewers independently abstracted all trials using a standardized form. A hierarchy of frequency and time domain HRV indices defined outcome. RESULTS: A random-effects model yielded an overall pooled standardized mean difference (SMD) between treatment and control groups of moderate magnitude across treatment classes, based on a composite of time and frequency domain indices (SMD=0.40, P<0.0001), or only time or frequency indices (SMD=0.37 and 0.43, respectively, both P<0.0001). This change was equivalent to an increase in standard deviation of all normal-to-normal RR intervals of 9.0 ms (95% Confidence Interval, CI, 7.3, 10.7 ms) or a relative increase of 15.9% (95% CI, 13.2, 18.6%). To detect HRV change of this magnitude, a hypothetical trial would require a sample size of 660 patients for conventional medications or 1232 patients for all treatment classes. CONCLUSION: Pharmacologic, biobehavioral and exercise strategies for secondary prevention of CAD significantly increase HRV. This review provides a framework to assist efforts to evaluate the contribution of HRV change to CAD prognosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hjr.0b013e3283030a97

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Canadian Task Force on Preventive Health Care. New grades for recommendations from the Canadian Task Force on Preventive Health Care. Can Med Assoc J 2003; 169:207-208.

Cited by

Sorted by citations

Authors
Nolan, R. P., Jong, P., Barry-Bianchi, S. M., Tanaka, T. H., & Floras, J. S.
Affiliations
  • University Health Network (CA)
  • Tsukuba University of Technology (JP)
Corresponding author
Nolan, Robert P.
Venue
European Journal of Cardiovascular Prevention & Rehabilitation
Published
2008-08
Volume
15
Issue
4
Pages
386-396
ISSN
1741-8267 (ISSN-L)
OpenAlex
W2055655271
Cited by
117
References
49
Citations by year
2026: 3 · 2025: 1 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 4 · 2020: 12 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 6 · 2014: 14 · 2013: 8 · 2012: 8
FWCI
1.11
Type
journal article
Language
en
Open access
closed
Locations
  • European Journal of Cardiovascular Prevention & Rehabilitation (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Heart and Stroke Foundation of Canada
  • Canadian Institutes of Health Research
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Rate Variability and Autonomic Control
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
heart rate variability, coronary artery disease, secondary prevention, beta-blockers, calcium channel blockers, ACE inhibitors, psychotropic drugs, biofeedback, relaxation training, exercise training, time-domain HRV, frequency-domain HRV indices, sample size determination, surrogate endpoints
MeSH terms
Behavior Therapy, Cardiovascular Agents, Coronary Artery Disease, Exercise Therapy, Heart Rate, Humans, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review